**Background:** The RespiFast RG Panel (Qiagen GmbH, Hilden, Germany) is a new qualitative multiplex NAAT to detect and differentiate 16 RNA viruses, 2 DNA viruses, and 4 bacteria, all of which can cause respiratory tract infections in humans. The RespiFast RG Panel contains 23 different RespiFast primer sets combined with 15 fluorescent-labeled SMART (single-tube multiplex amplification in real time) probes that enable the detection of 22 different pathogens plus an internal control and 2 amplification controls. The method involves a pre-amplification step (step 1) hat combines a reverse transcription step with a PCR step to amplify the target cDNA followed by two separate (Step 2) reactions. Detection was performed using a Melting Curve analysis on the Rotor-Gene Q MDx instrument.

**Methods:** A retrospective study included 139 samples (to date) from the 2014 to 2015 respiratory season which had been previously tested with an in-house real-time PCR consisting of 8 different duplex and triplex real-time PCRs (Bonzel et al, PIDJ 2008:27(7):589--594). Nucleic acid extraction was performed with the QIAGEN EZ1 and eluates were stored at −20 °C before being retested with the RespiFast RG Panel. The study is ongoing with a goal to test 230/230 samples in total.

**Results:** For the initial 139 samples we observed a high concordance between the two assays, for Influenza A (12/12), Influenza B (13/13), Bocavirus (10/10) and hMPV (12/13). For some other pathogens (RSV and Parainfluenza 3) discordances in detection rates were observed. The clarification for the reasons are still under investigation. Some low copy number samples (Coronavirus and Parainfluenzaviruses) could not be detected in RespiFast RG Panel, most likely due to the retrospective design, whereas 2 negative samples with the in-house assay were Rhinovirus/Enterovirus positive with the RespiFast RG Panel.

**Conclusion:** RespiFast RGPanel is a suitable tool for fast detection of a wide number of respiratory pathogens in a single assay.
